174 related articles for article (PubMed ID: 1975039)
1. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.
Heim M; Meyer UA
Lancet; 1990 Sep; 336(8714):529-32. PubMed ID: 1975039
[TBL] [Abstract][Full Text] [Related]
2. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
[TBL] [Abstract][Full Text] [Related]
3. Poor metabolisers of debrisoquine reveal their true colours.
Idle JR
Lancet; 1989 Nov; 2(8671):1097. PubMed ID: 2572815
[No Abstract] [Full Text] [Related]
4. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
5. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
[TBL] [Abstract][Full Text] [Related]
6. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
[TBL] [Abstract][Full Text] [Related]
7. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
8. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
[TBL] [Abstract][Full Text] [Related]
9. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.
Heim MH; Meyer UA
Methods Enzymol; 1991; 206():173-83. PubMed ID: 1686063
[No Abstract] [Full Text] [Related]
11. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
[TBL] [Abstract][Full Text] [Related]
12. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
13. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
[TBL] [Abstract][Full Text] [Related]
14. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
Meyer UA; Skoda RC; Zanger UM
Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
[TBL] [Abstract][Full Text] [Related]
16. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
[TBL] [Abstract][Full Text] [Related]
17. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
[TBL] [Abstract][Full Text] [Related]
18. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR
Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
[TBL] [Abstract][Full Text] [Related]
19. Molecular genotyping to predict debrisoquine hydroxylation phenotype.
Daly AK; Armstrong M; Idle JR
Lancet; 1990 Oct; 336(8719):889-90. PubMed ID: 1976926
[No Abstract] [Full Text] [Related]
20. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
